From Growth factor shows promise for Phelan-McDermid syndrome
"Last week, a separate set of researchers announced that the drug appears to be safe and effective in a trial of 53 adolescents and adults with Rett syndrome."
The inference is that IGF-1 was the drug being used instead of NNZ-2566. Only later on do you learn that:
"The Rett trial uses a modified form of IGF-1 that includes only the first three amino acids, but which may induce production of the full-length form in the brain"
I have noticed in a number of articles IGF-1 was being hyped and NNZ-2566 downplayed or not mentioned (as in the above announcement). To me IGF-1 is a competitor.
- Forums
- ASX - By Stock
- Wider autism efficacy potential for nnz-2566
NEU
neuren pharmaceuticals limited
Add to My Watchlist
1.21%
!
$14.19

From Growth factor shows promise for Phelan-McDermid syndrome...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$14.19 |
Change
0.170(1.21%) |
Mkt cap ! $1.754B |
Open | High | Low | Value | Volume |
$13.90 | $14.21 | $13.64 | $2.329M | 167.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 94 | $14.18 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$14.19 | 16 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 147 | 14.170 |
4 | 68 | 14.160 |
6 | 637 | 14.150 |
8 | 1267 | 14.140 |
8 | 1338 | 14.130 |
Price($) | Vol. | No. |
---|---|---|
14.180 | 469 | 7 |
14.190 | 629 | 5 |
14.200 | 842 | 6 |
14.210 | 3671 | 7 |
14.220 | 1067 | 4 |
Last trade - 12.43pm 08/07/2025 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |